Meiragtx Holdings plc (MGTX) fundamentals score
Meiragtx is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson’s disease and AIPL1-associated retinal dystrophy. Its clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 7.6 out of 10, Mixed fundamentals
- Growth: 9.2/10
- Profitability: 8.3/10
- Financial health: 8.5/10
- Earnings quality: 2.9/10
- Valuation: 7.0/10
Scores are calculated from Meiragtx Holdings plc’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10